ChinaBio(R) LLC Week in Review: 2012 China Life Science VC, M&A, and Partnering Climb

Published: Jan 28, 2013

by Richard Daverman, PhD

January 26, 2012 -- In 2012, China’s life science’s VC investment, M&A transactions, and partnering activity all rose substantially according to ChinaBio® data; Zhejiang Hisun Pharma in-licensed China rights to ThermoDox®, a liver cancer drug developed by Celsion Corporation, in a deal potentially worth hundreds of million of dollars; Simcere sold its 35% stake in Shanghai Celgen Bio-Pharmaceutical for $48.6 million; Huapont Pharma will partner with Yes Biotech, a Canadian company, to develop a new psoriasis treatment; Xceleron of the US and Crystal Pharmatech of Suzhou formed an early-stage CRO partnership; Wilex, a US diagnostics marker, engaged GeneDiagnostics to distribute its cancer biomarker test; Sihuan Pharma received SFDA approval to begin clinical trials of its innovative antibiotic; and Can-Fite Biopharma, an Israeli firm, will transfer its drug production to China. More details….

Stock Symbols: (SHA: 600267) (NSDQ: CLSN) (NYSE: SCR) (SHE: 002004) (HK: 0460) (TASE: CFBI; OTCBB: CANFY)

Back to news